Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study.
Saved in:
| Title: | Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study. |
|---|---|
| Authors: | Tang J; Centre of Colorectum Cancer, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.; Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine, Nanjing, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, China., Wang L; Centre of Colorectum Cancer, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.; Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine, Nanjing, Jiangsu, China., Yang S; Centre of Colorectum Cancer, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.; Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine, Nanjing, Jiangsu, China.; Department of General Surgery, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, China., Peng W; Centre of Colorectum Cancer, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.; Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine, Nanjing, Jiangsu, China., Zhang Y; Centre of Colorectum Cancer, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.; Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine, Nanjing, Jiangsu, China., Zhang Y; Centre of Colorectum Cancer, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.; Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine, Nanjing, Jiangsu, China., Jin K; Centre of Colorectum Cancer, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.; Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine, Nanjing, Jiangsu, China., Wang X; Centre of Colorectum Cancer, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. wxw0213@njmu.edu.cn.; Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine, Nanjing, Jiangsu, China. wxw0213@njmu.edu.cn.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, China. wxw0213@njmu.edu.cn., Feng Y; Centre of Colorectum Cancer, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. fengyifei1982@163.com.; Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine, Nanjing, Jiangsu, China. fengyifei1982@163.com., Sun Y; Centre of Colorectum Cancer, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. sunyueming@njmu.edu.cn.; Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine, Nanjing, Jiangsu, China. sunyueming@njmu.edu.cn.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, China. sunyueming@njmu.edu.cn. |
| Source: | Signal transduction and targeted therapy [Signal Transduct Target Ther] 2026 May 04; Vol. 11 (1). Date of Electronic Publication: 2026 May 04. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2059-3635 |
|---|---|
| DOI: | 10.1038/s41392-026-02683-8 |
